Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celera Genomics (CRA) -- Ignore unavailable to you. Want to Upgrade?

To: Walkingshadow who wrote (473)	6/26/2000 10:32:00 AM
From: allen menglin chen	Read Replies (1) \| Respond to of 746

Venter writes for LATimes latimes.com

To: Walkingshadow who wrote (473)	6/26/2000 1:50:00 PM
From: gao seng	Read Replies (3) \| Respond to of 746

Clinton may not have as much pull as I expected, but here is some news that may affect the price. I have been expecting more news than just the assembly. Monday June 26, 1:44 pm Eastern Time Celera says Immunex signs up for its genomic databases NEW YORK, June 26 (Reuters) - Celera Genomics (NYSE:CRA - news) said on Monday that it as signed up Seattle-based biotech company Immunex Corp (NasdaqNM:IMNX - news) as a subscriber to its genomic databases. Craig Venter, president and chief scientific officer of Celera, said at a press conference in Washington that he had learned about Immunex' decision earlier Monday as President Clinton was announcing that Celera and the publicly funded Human Genome Project had separately mapped the collection of human genes. Venter did not provide details about the deal with Immunex, which markets the hot-selling arthritis drug Enbrel. Immunex is among about a half dozen U.S. and Japanese drugmakers that have in the last 18 months signed deals to use Celera's databases, which describe the sequence of four chemicals that form the genetic blueprint of humans and other organisms, including the fruit fly. Earlier subscribers to Celera's databases have each agreed to pay between $25 million and $50 million to use them for periods of between 3-5 years. They include No. 1 U.S. drugmaker Pfizer Inc (NYSE:PFE - news) and Takeda , Japan's largest drugmaker. biz.yahoo.com